Avanafil (Stendra)

Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012, and by EMA on June 21, 2013 Avanafil is known by the trademark names Stendra and Spedra and was developed by Vivus Inc. In July 2013, Vivus announced a partnership with Menarini Group, which will commercialise and promote Spedra in over 40 European countries plus Australia and New Zealand. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has a very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 30-45 minutes. About two-thirds of the participants were able to engage in sexual activity within 15 minutes.

  • Pharma Grade

    Super Avana 160

    £30
     
    Add to cart

  • Pharma Grade

    Extra Super Avana 260

    £35
     
    Add to cart

  • Pharma Grade

    Avanafil 200 mg

    £40
     
    Add to cart

  • Pharma Grade

    Avana 100

    £35
     
    Add to cart

  • Pharma Grade

    Avana 50

    £20
     
    Add to cart